Incorporating molecular tools into clinical trials and treatment for gliomas?

Current Opinion in Neurology

Volumn 20, Issue 6, 2007, Pages 708-711

  Lassman, Andrew B ^a   Holland, Eric C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chromosome 19q; Chromosome 1p; Epidermal growth factor receptor; Glioma; MGMT; PTEN

Indexed keywords

CARMUSTINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TEMOZOLOMIDE;

CHROMOSOME 19Q; CHROMOSOME 1P; CORRELATION ANALYSIS; DNA DETERMINATION; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; MEDICAL PRACTICE; MOLECULAR BIOLOGY; MONOTHERAPY; OLIGODENDROGLIOMA; PROGNOSIS; REVIEW; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY; GLIOMA; HUMANS; MOLECULAR BIOLOGY; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 36049031462     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3282f1a05c     Document Type: Review

References (29)

1. Bailey P, Cushing H. A classification of the tumors of the glioma group on a histo-genetic basis with a correlated study of prognosis. Philadelphia: JB Lippincott Co; 1926.
2. Kleihues P, Cavanee W. Pathology and genetics of tumours of the nervous system. Lyon: WHO/IARC; 2000.
3. CBTRUS. Statistical report: primary brain tumors in the United States, 1995-1999. Central Brain Tumor Registry of the United States; 2002. http://www.cbtrus.org [accessed 13 September 2007].
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996.
5. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003.
6. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004; 4:296-307.
7. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22:133-142.
8. Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005; 23:357-361.
9. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006; 12:4899-4907.
10. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005; 23:5294-5304.
11. Raizer JJ, Abrey LE, Wen P, et al. A phase II trial of erlotinib (OSI-774) in patients with recurrent malignant gliomas not on EIAEDs [abstract]. J Clin Oncol 2004; 22:1502.
12. Lieberman FS, Cloughesy T, Malkin M, et al. Phase I-II study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy [abstract]. J Clin Oncol 2003; 22:105.
13. Conrad C, Friedman H, Reardon D, et al. A phase I/II trial of single-agent PTK 787/ZK222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme [abstract]. J Clin Oncol 2004; 22:1512.
14. van den Bent M, Brandes AA, van Oosterom A, et al. Multicentre phase II study of imatinib mesylate (Gleevec) in patients with recurrent glioblastoma [abstract]. Neuro Oncol 2004; 6:383.
15. Vogelbaum MA, Peerboom G, Stevens G, et al. Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: interim results [abstract]. J Clin Oncol 2004; 22:1558.
16. Yung A, Vredenburgh J, Cloughesy T, et al. Erlotinib HCl for glioblastoma multiforme in first relapse, a phase II trial [abstract]. J Clin Oncol 2004; 22:1555.
17. Brandes AA, Tosoni A, Amista P, et al. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 2004; 63:1281-1284.
18. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353:2012-2024.
19. Bianco R, Shin I, Ritter CA, et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22:2812-2822.
20. Kokubo Y, Gemma A, Noro R, et al. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 2005; 92:1711-1719.
21. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-13311.
22. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005; 97:880-887.
23. Lassman AB, Rossi MR, Raizer JJ, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005; 11:7841-7850; Erratum in Clin Cancer Res 2005; 12:322.
24. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001; 7:839-845.
25. Cairncross J, Ueki K, Zlatescu M, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90:1473-1479.
26. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006; 24:2707-2714.
27. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24:2715-2722.
28. Abrey LE, Louis DN, Paleologos N, et al. Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol 2007; 9:314-318. This study demonstrates heterogeneity of treatment recommendations for oligodendroglioma despite availability of1p and 19q deletion status.
29. Lassman AB, Cloughesy TF, DeAngelis LM, et al. Chemotherapy with deferred radiotherapy for newly diagnosed anaplastic oligodendroglioma and anaplastic mixed glioma [abstract]. Neuro Oncol 2006; 8:445.